Suilysin Stimulates the Release of Heparin Binding Protein from Neutrophils and Increases Vascular Permeability in Mice by Shaolong Chen et al.
fmicb-07-01338 August 24, 2016 Time: 15:4 # 1
ORIGINAL RESEARCH










University of Hyderabad, India
Peter Valentin-Weigand,







†These authors have contributed
equally to this work and are senior
authors.
Specialty section:
This article was submitted to
Microbial Immunology,
a section of the journal
Frontiers in Microbiology
Received: 01 May 2016
Accepted: 15 August 2016
Published: 26 August 2016
Citation:
Chen S, Xie W, Wu K, Li P, Ren Z,
Li L, Yuan Y, Zhang C, Zheng Y,
Lv Q, Jiang H and Jiang Y (2016)
Suilysin Stimulates the Release
of Heparin Binding Protein from




Suilysin Stimulates the Release of
Heparin Binding Protein from
Neutrophils and Increases Vascular
Permeability in Mice
Shaolong Chen, Wenlong Xie, Kai Wu, Ping Li, Zhiqiang Ren, Lin Li, Yuan Yuan,
Chunmao Zhang, Yuling Zheng, Qingyu Lv, Hua Jiang*† and Yongqiang Jiang*†
State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China
Most of the deaths that occurred during two large outbreaks of Streptococcus suis
infections in 1998 and 2005 in China were caused by streptococcal toxic shock
syndrome (STSS), which is characterized by increased vascular permeability. Heparin-
binding protein (HBP) is thought to mediate the vascular leakage. The purpose of this
study was to investigate the detailed mechanism underlying the release of HBP and
the vascular leakage induced by S. suis. Significantly higher serum levels of HBP were
detected in Chinese patients with STSS than in patients with meningitis or healthy
controls. Suilysin (SLY) is an exotoxin secreted by the highly virulent strain 05ZYH33, and
it stimulated the release of HBP from the polymorphonuclear neutrophils and mediated
vascular leakage in mice. The release of HBP induced by SLY was caused by a calcium
influx-dependent degranulation. Analyses using a pharmacological approach revealed
that the release of HBP induced by SLY was related to Toll-like receptor 4, p38 mitogen-
activated protein kinase, and the 1-phosphatidylinositol 3-kinase pathway. It was also
dependent on a G protein-coupled seven-membrane spanning receptor. The results of
this study provide new insights into the vascular leakage in STSS associated with non-
Group A streptococci, which could lead to the discovery of potential therapeutic targets
for STSS associated with S. suis.
Keywords: heparin binding protein, Streptococcus suis-associated streptococcal toxic shock syndrome, suilysin,
vascular permeability
INTRODUCTION
Streptococcus suis has been recognized as an emerging zoonotic pathogen (Staats et al., 1997; Lun
et al., 2007; Segura, 2009; Wertheim et al., 2009; Gottschalk et al., 2010). Since the first human
infection was identified in 1968 in Denmark (Perch et al., 1968), more than 400 cases of S. suis
infection have been reported worldwide during the subsequent four decades (Lun et al., 2007). Most
of these cases presented as meningitis, septicemia, endocarditis, arthritis, or pneumonia (Staats
et al., 1997; Lun et al., 2007). Two large outbreaks of S. suis serotype 2 (S. suis 2) infection in 1998
and 2005 in China affected more than 200 people and led to 52 deaths. Most of these deaths were
caused by streptococcal toxic shock syndrome (STSS; Hu et al., 2000; Tang et al., 2006; Yu et al.,
2006).
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Streptococcal toxic shock syndrome associated with group
A streptococci (GAS) is well recognized. A massive over-
stimulation of T-cells is believed to be associated with STSS
(Brown, 2004; Low, 2013). Superantigens (SAgs), including the
streptococcal pyrogenic exotoxin serotypes A, C, and G–M as
well as the streptococcal mitogenic exotoxin Z are involved
in the molecular and pathological mechanism underlying STSS
associated with GAS (Brosnahan and Schlievert, 2011). In
addition to the SAgs, M protein, which is a highly conserved
cell-surface protein of GAS that can induce strong inflammation,
might also contribute to the development of STSS (Pahlman
et al., 2006). However, S. suis is a non-GAS pathogen, and does
not contain DNA sequences that are homologous to the genes
encoding the SAgs or M protein, indicating that molecules other
than the SAgs or M protein might be involved in the mechanism
underlying the STSS outbreaks associated with S. suis in China
(Tang et al., 2006).
Streptococcal toxic shock syndrome caused by S. suis 2, is
characterized by acute high fever, vascular collapse, hypotension,
shock, petechia, disseminated intravascular coagulation, and
multiple organ failure (Tang et al., 2006; Yu et al., 2006).
Vascular leakage is a fundamental mechanism of shock. Active
polymorphonuclear neutrophils (PMNs) have been shown to
release a broad spectrum of cytokines and other molecules
that induce increased vascular permeability (Gautam et al.,
1998, 2000, 2001). One of these molecules, heparin-binding
protein (HBP), is thought to be a key mediator that induces
vascular leakage (Gautam et al., 2001; Edens and Parkos, 2003).
HBP is also known as azurocidin or CAP37, and has diverse
functions. It is usually stored in the azurophilic granules and
secretory vesicles in the PMNs (Tapper et al., 2002). The
molecular mechanism underlying the release of HBP from the
PMNs has been extensively investigated. Bacterial-derived M
protein has been shown to bind to fibrinogen and interact
with the ß2-integrins on the surface of the PMNs, stimulating
the release of HBP (Herwald et al., 2004). HBP can also be
released from the PMNs by other mechanisms, including PMN
degranulation mediated by streptolysin O (Nilsson et al., 2006)
and the lipid leukotriene B4 (LTB4)-mediated stimulation of
the BLT1 receptor and phosphatidylinositol 3-kinase (PI3K)
intracellular pathway (Di Gennaro et al., 2009). The molecular
and pathological mechanisms underlying STSS that are not
associated with GAS remain poorly understood (Hashikawa et al.,
2004; Ekelund et al., 2005). In this study, we focused on the highly
virulent S. suis 2 strain 05ZYH33 to investigate the molecular
mechanism underlying the release of HBP from the PMNs and
the induced vascular leakage. This strain was originally isolated
from a patient who died from STSS during the S. suis outbreak in
2005 in Sichuan, China.
MATERIALS AND METHODS
Reagents
Recombinant human HBP (rHBP, Cat.No.2200-SE-050/CF),
polyclonal goat anti-human HBP antibody (Cat.No.AF2200),
and monoclonal mouse anti-human HBP antibody
(Cat.No.MAB2200) were purchased from R&D (Minneapolis,
MN, USA). CLI-095 [a specific inhibitor of Toll-like receptor
4 (TLR4), Cat.No.tlrl-cli95] and OxPAPC (a TLR4 non-
specific inhibitor, Cat.No.tlrl-oxp1) were obtained from
Invivogen (Hong Kong, China). Escherichia coli O26:B6
lipopolysaccharide (LPS, Cat.No.L2654), EGTA (a calcium
chelator, Cat.No.E3889), U73122 (a phospholipase C inhibitor,
Cat.No.U6756), PD98059 (a mitogen-activated protein kinase
pathway inhibitor, Cat.No.P215), SB202474 (a negative control
for SB203580), SB203580 (a p38 MAPK inhibitor), Wortmannin
(a PI3K inhibitor, Cat.No.F9128) and Genistein (a receptor
tyrosine kinase inhibitor, Cat.No.G6649) were purchased from
Sigma–Aldrich (St. Louis, MO, USA). Pertussis toxin (PTX; a
receptor inhibitor coupled to G protein) was kindly provided
by the National Vaccine and Serum Institute (Beijing, China).
The PMN Elastase Human ELISA Kit (Cat.No.ab119553) and
the Lactoferrin Human ELISA kit (Cat.No.ab108882) were from
Cayman Chemical (Ann Arbor, MI, USA).
Blood Specimens from Patients
All the blood specimens were kindly provided by the Chinese
Center for Disease Control and Prevention and kept anonymous.
The Chinese Center for Disease Control Human Research
Protection Office approved the retrospective testing using
anonymous samples. Blood specimens from 13 healthy
individuals and 14 patients, including eight with meningitis
and six with STSS, were used in this study.
Isolation of Polymorphonuclear
Neutrophils (PMNs)
Human PMNs were isolated from freshly heparinized blood
that was collected by gradient centrifugation. Red blood cells
were separated by 6% dextran (Sigma–Aldrich), and then the
PMNs were isolated using density gradient media containing
70% Percoll (Pharmacia, New York, NY, USA) and Ficoll (GE
Healthcare, Little Chalfont, UK). The purified PMNs were
suspended in Hanks’ balanced salt solution (HBSS, Invitrogen,
Carlsbad, CA, USA) at a concentration of 2 × 106 cells/mL. The
cellular purity was greater than 97% as indicated by Wright–
Giemsa staining. The survival rate was greater than 97% as
assessed by Trypan blue staining. The purified PMNs were used
in the following experiments.
PMN Stimulation
One hundred microliters of human whole blood or 1.0 × 106
isolated PMNs were diluted in HBSS to a final volume of 1.0 mL
and incubated with various putative stimulants at 37◦C for
30 min. The HBP levels in the blood samples or the release
of HBP from PMNs were subsequently determined. Cells were
centrifuged at 300 × g for 15 min and HBP levels in the
supernatant were analyzed by a sandwich ELISA or a Western
blot. The amount of HBP in the cell lysate of the whole blood
samples or the PMNs obtained by treatment with 1% Triton
X-100 was determined and considered as the total HBP. The
percentage of the HBP level in the supernatant relative to the total
HBP level was calculated.
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Determination of HBP Levels by ELISA
The HBP levels in the supernatant of the whole blood sample
or the PMN suspension were determined by a sandwich-based
ELISA as previously described (Tapper et al., 2002). Briefly,
microtiter plates (Costar, Corning Inc., Corning, NY, USA)
were coated with a polyclonal goat anti-human HBP antibody
(100 µL of 0.5 µg/mL antibody solution). After washing and
blocking, 100 µL of sample was added to duplicate wells and
incubated at 37◦C for 1 h or 4◦C overnight. The standard
for quantifying the HBP levels was rHBP. After a thorough
washing, the plates were incubated with a monoclonal mouse
anti-human HBP antibody (100 µL of 1 µg/mL antibody
solution) at 37◦C for 1 h or 4◦C overnight. A horseradish
peroxidase (HRP)-conjugated antibody against mouse IgG
(1:8,000, ZSGB-Bio, Beijing, China) was added to detect the
primary antibody. The plate was read in a microtiter plate
reader (Thermo Fisher Scientific, Waltham, MA, USA) at
450 nm.
Detection of HBP by Western Blotting
Thirty microliters of the supernatant of a whole blood
sample or a PMN suspension were separated by 12% (w/v)
polyacrylamide gel electrophoresis in the presence of 1%
(w/v) sodium dodecyl sulfate (SDS-PAGE) and transferred
to a polyscreen polyvinylidene difluoride membrane (Merck
Millipore, Billerica, MA, USA). The membrane was first
blocked in 5% (w/v) non-fat milk in phosphate-buffered saline
(PBS) supplemented with 0.05% (v/v) Tween 20 at room
temperature for 1 h, and incubated with the polyclonal goat
anti-human HBP antibody (1 µg/mL) at 4◦C overnight. After
intensive washing, the membrane was incubated with HRP-
labeled mouse anti-goat IgG (1:8,000, ZSGB-Bio) for 1 h. The
immunoblots were analyzed using a Gel Imaging System and
the Quantity One Software version 4.0 (Bio-Rad, Hercules, CA,
USA).
Bacterial Strains and Culture Conditions
The highly virulent S. suis serotype type 2 strain 05ZYH33
(GenBank accession number NC_009442), which was originally
isolated from a patient who died from STSS during the
S. suis outbreak in 2005 in Sichuan, China, was used in
this study. A suilysin gene (sly) deletion mutant of 05ZYH33
(1sly) was constructed via the in-frame replacement of the
SSU05_1403 gene with a chloramphenicol (Cm) resistance
cassette. The complement strain of the 1sly mutant (C1sly)
was established by transforming the mutant with a pAT18
vector that expressed the sly gene. These strains were previously
constructed in our laboratory (He et al., 2014). All the
bacterial strains were grown on Colombia agar plates (BD
Biosciences, San Jose, CA, USA) containing 5% sheep’s
blood at 37◦C under 5% CO2. The bacterial suspensions
were grown in Todd-Hewitt broth (THB, BD) for 8 h
without agitation, and the supernatants were harvested for
future experiments. Five microgram per mL of Cm or
8 µg/mL Em (Sigma–Aldrich) were added to the media for
selection.
Purification of Native and Recombinant
Suilysin (SLY)
Native SLY was purified as previously described (Jacobs
et al., 1994; Lv et al., 2014). Briefly, the supernatant from a
large-scale 05ZYH33 culture was collected by continuous-flow
centrifugation and filtered through a ceramic filer with a 0.8 µm
pore size at 4◦C, and concentrated to 150 ml using 10,000-
nominal-molecular-weight-limit filters (PTCG; Minitan; Merck
Millipore). The concentrated supernatants were sterilized by
filtration through a 0.2 µm pore size filer (Falcon, Thermo
Fisher Scientific), loaded onto a Superose-12 gel filtration
column (FPLC, Pharmacia), and eluted into 40 mM PBS (pH
7.2) supplemented with 0.5 M NaCl. The elution fractions
were collected and analyzed by SDS-PAGE. The recombinant
SLY and the non-hemolytic sly mutant SLY (P353V) used in
this study were previously constructed and purified in our
laboratory (Ren et al., 2012). The endotoxin level in the native
suilysin (SLY) was less than 0.03 EU/mL. The endotoxins
that remained in the purified recombinant SLY were removed
with Triton X-114 (Liu et al., 1997) and were less than
0.5 EU/mL before the purified recombinant SLY was used in
experiments.
Measurement of Superoxide Anion
Production
Superoxide anion production was determined as previously
described (Nilsson et al., 2006). PMNs were stimulated with
0.50, 0.75, or 1.0 µg/mL native SLY or with the supernatants
from 05ZYH33 cultures at 37◦C for 20 min. The PMNs were
kept on ice for 10 min to terminate the stimulation, collected
by centrifugation at 200 × g for 15 min and re-suspended
in 0.25 ml Krebs-Ringer phosphate (KRG, 120 mM NaCl,
4.9 mM KCl, 1.7 mM KH2PO4, 1.2 mM MgSO4·7H2O, 8.3 mM
Na2HPO4·2H2O, 10 mM glucose, pH 7.3) buffer containing
0.1 mM cytochrome C. Superoxide production from the PMNs
was induced by incubation with 200 ng/mL phorbol myristate
acetate (PMA) at 37◦C for 20 min. The PMNs were pelleted, and
the absorbance of the supernatants was determined at 550 nm.
To determine baseline levels of superoxide anion production,
the PMNs were incubated with KRG buffer without cytochrome
C. KRG buffer without PMNs was used as the blank reference.
The HBP in the supernatant was also determined by Western
blotting.
Electron Microscopy
The integrity of the PMNs was assessed by electron microscopy.
After incubation with 1.0 µg/mL native SLY, the PMNs were
spread onto poly-L-lysine coated coverslips, incubated at 37◦C
for 1 h, and fixed in 2.5% (v/v) glutaraldehyde at room
temperature for 30 min. The PMNs were dehydrated in an
ascending ethanol series from 50% (v/v) to absolute ethanol
(10 min per step). The specimens were subjected to critical
point drying in CO2 with absolute ethanol as an intermediate
solvent, mounted on copper holders, sputtered with 30 nm
palladium and gold, and examined in an S-3400N scanning
electron microscope.
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Flow Cytometry
A total of 2 × 106 PMNs were incubated with 1.0 µg/mL native
SLY at 37◦C for 30 min with rotation and subsequently kept
on ice. The expression of markers for PMN degranulation was
assessed with PE conjugated mouse anti-human CD63 (1:100),
APC conjugated mouse anti-human CD11b (1:100), and FITC
conjugated mouse anti-human CD66b (1:100, BD Biosciences).
Isotype-matched antibodies were used as negative controls. The
fluorescence intensity of each sample was determined on an
Accuri C6 flow cytometer (BD Biosciences). The data were
analyzed using the FlowJo software (FlowJo LLC, Ashland, OR,
USA).
Determination of Calcium Mobilization
Polymorphonuclear neutrophils were loaded with 5 µM Fura-
3 AM (Invitrogen) in HBSS at 37◦C for 1 h and plated
into a confocal dish (Thermo Fisher Scientific). Putative PMN
stimulants were added to the confocal dish. The PMNs were
monitored with a FV1000 confocal laser-scanning microscope
(Olympus, Tokyo, Japan) for 200 s. The mean fluorescence
intensity of at least eight cells was recorded.
In vivo Miles Assay for the Assessment
of Vascular Permeability
The Miles assay was performed on 8-week-old female C57BL/6J
mice to evaluate the effects of SLY on vascular permeability.
C57BL/6J mice were purchased from the Animal Care Center
of the Academy of Military Medical Science (AMMS; Beijing,
China) and housed in a clean room with unlimited access to
food and water. TLR4 knockout mice C57BL/10ScNJNju and
control mice were obtained from the Model Animal Research
Center of Nanjing University. The mice were randomly divided
into four groups and intradermally injected in the abdomen
with 100 µL THB, 05ZYH33-supernatant, 1sly-supernatant,
or C1sly-supernatant. Four hours after the injection, 100 µL
Evans blue dye solution (2.5%, Ourchem, Sinopharm) was
injected via the tail vein. The mice were sacrificed by cervical
dislocation 30 min after the Evans blue injection, and equal
areas (20 mm × 20 mm) of skin surrounding the intradermal
injection site were removed from each mouse and completely
dried in an oven. The Evans blue dye was eluted from
the oven-dried skin into 1 mL formamide (Sinopharm) at
55◦C for 2 days, and quantified by spectrophotometry at
630 nm.
Statistics
Statistical analyses were performed using the Prism 5 software
(GraphPad Software, La Jolla, CA, USA). For normally
distributed data, a comparison between two groups was
made using Student’s t-test, and comparisons among multiple
groups were done with a one-way analysis of variance.
The P-value was for a 2-sided test, and P < 0.05 was
considered as statistically significant. All data were expressed
as the mean ± standard deviation. A rank-sum test was
performed to compare the HBP levels in the patients versus the
controls.
Study Approval
All the protocols for handling the patient blood specimens or
experiments using blood from healthy donors were approved by
the Institutional Medical Ethics Committee of AMMS. A signed
informed consent form was obtained from each patient or a
guardian and healthy volunteer. The entire study was conducted
in accordance with the Declaration of Helsinki.
All experimental procedures involving mice were conducted
in strict accordance with the recommendations in the Guide for
the Care and Use of Laboratory Animals of the National Institutes
of Health and State Key Laboratory of Pathogens and Biosecurity
of the Beijing Institute of Microbiology and Epidemiology and
approved by the Institutional Animal Care and Use Committee
of the AMMS under Permit No. IACUC of AMMS-2014-031.
Animal welfare was considered and suffering was minimized.
RESULTS
Suilysin from the Strain 05ZYH33
Induced the Release of HBP from PMNs
Heparin-binding protein has been reported as a potential
biomarker of severe sepsis and septic shock (Linder et al., 2009,
2012; Chew et al., 2012) and as an indicator of vascular leakage
(Johansson et al., 2009). A comparison of serum HBP levels
between patients with S. suis-associated STSS versus patients
without STSS or healthy individuals revealed that the serum HBP
levels in patients with STSS were significantly higher than those in
patients with meningitis or healthy controls (46.61± 9.49 ng/mL
vs. 11.52 ± 5.20 ng/mL or 1.84 ± 0.96 ng/mL, respectively;
P = 0.0007, Figure 1), which suggested that HBP is released
during the progression of STSS in patients infected with S. suis.
Both the ELISA and Western blotting analyses demonstrated that
the bacterial culture of the highly virulent S. suis strain 05ZYH33
significantly increased the release of HBP in the whole blood of
healthy individuals (Figure 2A) and in purified PMN suspension
(Figures 2B,C), whereas THB media without 05ZYH33 failed
to induce the release of HBP in a whole blood sample or a
PMN suspension. The positive control for the Western blot was
rHBP. The molecular weight of native HBP is approximately
31 kDa, while rHBP appears to be approximately 39 kDa on
a Western blot owning to its carboxyl-terminal polyhistidine
tag (Figure 2C). These results suggest that strain 05ZYH33
stimulates the release of HBP from PMNs.
The molecule responsible for inducing the release of HBP
was identified. Supernatants of the 05ZYH33 culture, but not
the 05ZYH33 bacterial cells, significantly induced the release
of HBP in whole blood samples (P < 0.001, Figure 3A). Heat
treatment of the supernatants significantly reduced the release
of HBP in the whole blood samples (P < 0.001, Figure 3B),
indicating that the specific factor(s) could be proteins. Therefore,
the proteins in the supernatants were isolated by anion-exchange
and hydrophobic interaction chromatography. The proteins in
the elution fractions that markedly stimulated the release of
HBP were separated by SDS-PAGE, and two major protein
bands at approximately 58 and 35 kDa appeared on the gel
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FIGURE 1 | The serum HBP levels were significantly increased in
patients with STSS compared with patients without STSS or healthy
individuals. The serum HBP levels of healthy individuals (n = 13), patients
infected with S. suis presenting meningitis (n = 8), and patients infected with
S. suis presenting STSS (n = 6) were determined by ELISA. Data were
analyzed by a rank-sum test. ∗∗∗ indicates a significant difference between
patients with STSS vs. controls, P = 0.0007.
(Figure 3C). Mass spectrometry revealed that the 58 kDa protein
was SLY, and the 35 KDa protein was L-lactate dehydrogenase
(LDH; Supplementary Table S1). Recombinant LDH failed to
stimulate the release of HBP from PMNs (Figure 3D), which
suggests that LDH was not the molecule that induced the
release of HBP. Therefore, SLY is a likely candidate for the
substance that releases HBP. Supernatants of the sly gene deletion
mutant strain of 05ZYH33 (1sly) did not stimulate the release
of HBP, while the supernatants of the complement strain for
1sly (C1sly) restored the stimulation of the release of HBP
(P < 0.01, Figure 3E). Furthermore, Western blotting showed
that purified native SLY (nSLY) stimulated the release of HBP
from the PMNs, but a bacterial culture of 1sly strain failed to
do so (Figure 3F). Taken together, these findings suggest that
SLY secreted by 05ZYH33 induces the release of HBP from the
PMNs.
Suilysin Stimulated the Release of HBP
by Promoting PMN Degranulation
Heparin-binding protein is usually stored in azurophilic granules
and secretory vesicles in the PMNs and released by cell lysis
or via degranulation after the activation of a series of signal
transduction pathways (Borregaard and Cowland, 1997; Tapper
et al., 2002). We can infer that a high concentration of SLY
could lyse the PMNs and release the stored HBP, while a sub-
cytolytic concentration would interact with the cell membrane
receptor and could possibly trigger PMN degranulation. Different
concentrations of nSLY (0.50–1.0 µg/mL) did not affect the
production of superoxide anions from the PMNs (Figure 4A),
while the release of HBP from the PMNs was SLY dose-dependent
(Figure 4B), suggesting that the PMNs remained viable when
treated with nSLY. These findings indicate that cell lysis is not
related to the release of HBP mediated by SLY. Scanning electron
microscopy demonstrated that the PMNs exhibited membrane
blebs when treated with 1.0 µg/mL nSLY (Figure 4D) and
the control did not exhibit such blebs (Figure 4C), suggesting
that the degranulation might be induced by nSLY. A flow
cytometry analysis revealed the significant up-regulation of
markers for azurophilic granules (CD63), secondary/tertiary
granules and secretory vesicles (CD11b), and specific granules
(CD66b, also named CD67) at the plasma membrane after the
PMNs were incubated with recombinant SLY (rSLY), but the
recombinant factor H-binding protein (rFhb – a S. suis cell
wall protein that was purified using the same methods) was
not up-regulated. This implies that the granular vesicles in the
PMNs were mobilized for degranulation (Figures 4E–G). Other
proteins stored in the neutrophil granules, including elastase
from the azurophilic granules and lactoferrin from the secondary
granules, were released when the neutrophils were incubated with
nSLY or the 05ZYH33-supernatant (Figures 4H,I). All of these
results suggest that SLY induces the release of HBP via PMN
degranulation.
The Release of HBP Induced by Suilysin
Was Dependent on the Ca2+ Influx
An increased cytosolic Ca2+ concentration has been shown to
promote PMN degranulation via the mobilization of intracellular
granules and cytoskeleton rearrangements (O’Flaherty et al.,
1991; Lacy, 2006; Lacy and Eitzen, 2008). Thus, the SLY-induced
release of HBP might also be Ca2+-dependent. Indeed, the
release of HBP induced by the bacterial culture supernatants
was completely abolished in the presence of EGTA (P < 0.0001,
Figure 5A), suggesting that the release of HBP is dependent
on extracellular Ca2+. The measurement of intracellular Ca2+
revealed that nSLY (1 µg/mL) induced a rapid increase in the
intracellular Ca2+ concentration in standard HBSS, and that the
Ca2+ increase was completely abolished by EGTA or in Ca2+-
free HBSS (Figure 5B). N-formylmethionyl-leucylphenylalanine
(fMLP) served as a positive control and LPS was used as a
negative control (Figures 5B,C). These results indicate that
SLY induced the Ca2+ influx. A constructed non-hemolytic sly
mutant SLY (P353V; Xu et al., 2010; Du et al., 2013) could
neither induce calcium mobilization (Figure 5B), nor evoke the
secretion of HBP (Supplementary Figure S1), suggesting that the
SLY-induced release of HBP was dependent on the Ca2+ influx.
Supernatants of 05ZYH33 consistently induced a Ca2+ influx,
whereas THB media and supernatants of the 1sly mutant did
not induce a Ca2+ influx (Figure 5C). The Ca2+ influx induced
by the 05ZYH33 supernatant was also completely abolished
by EGTA (Figure 5C). All of these results indicated that the
Ca2+ influx plays a critical role in the release of HBP induced
by SLY.
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FIGURE 2 | 05ZYH33 cultures induced the release of HBP in whole blood samples and purified PMN suspension. (A,B) 05ZYH33 cultures significantly
induced the release of HBP in human whole blood samples (A) and purified PMN suspensions (B). Whole blood samples or purified PMN suspensions were
incubated with 05ZYH33 cultures or THB (control) for 30 min at 37◦C. The HBP level in the supernatants was measured by ELISA. The total cell lysate following
Triton X-100 treatment was used as the positive control. Data are expressed as the mean ± SD. An unpaired Student’s t-test was used. ∗∗P < 0.01, ∗P < 0.05.
(C) Western blotting results of release of HBP from human purified PMN suspensions. rHBP and Triton X-100 were used as positive controls.
The Release of HBP Induced by Suilysin
Was Dependent on the TLR4 Receptor,
p38 MAPK, and the PI3K Pathways, as
well as GPCR
To investigate possible mechanisms and the key molecules
involved in release of HBP, inhibitors were commonly used in
this study because of the lack of suitable cell lines for investigating
the release of HBP induced by SLY, and direct siRNA transfection
into PMNs could cause activation of the PMNs and the release of
HBP (data not shown).
Some cholesterol-dependent cytolysin (CDC) family
members, such as anthrolysin O, perfringolysin O, listeriolysin O,
streptolysin O, and pneumolysin, have been reported to interact
with TLR4 (Malley et al., 2003; Park et al., 2004; Srivastava et al.,
2005). SLY also belongs to the CDC family, and results from
our previous study have shown that SLY interacts with TLR4 to
induce an inflammatory response (Bi et al., 2015). In this study,
our results demonstrated that both the TLR4 specific inhibitor
CLI-095 (Figure 6A), which blocks the intracellular domain of
TLR4, and the TLR4 non-specific inhibitor OxPAPC (Figure 6B),
which competes with other ligands including CD14, LBP, and
MD2 for receptor binding, significantly reduced the release of
HBP induced by the 05ZYH33 supernatant. The results for both
inhibitors were significant at P < 0.0001. This suggests that the
release of HBP induced by SLY could be dependent on TLR4.
We then used a pharmacological approach to further investigate
the signaling pathway underlying the SLY-induced release of
HBP. The phospholipase C inhibitor U73122 (Figure 6C) and
the MAPK pathway inhibitor PD98059 (Figure 6D) did not
affect the release of HBP, whereas the p38 MAPK inhibitor
SB203580 (Figure 6E) and the PI3K inhibitor Wortmannin
(Figure 6F) markedly reduced HBP secretion (both P < 0.0001).
We confirmed that a time-dependent increase in the level of
phosphorylated p38 MAPK occurred in the presence of nSLY
(1.0 µg/ml; Supplementary Figure S2). Other receptor inhibitors
such as the GPCR inhibitor PTX significantly inhibited the
release of HBP (P < 0.0001, Figure 6G), but Genistein, an
inhibitor of the receptor tyrosine kinases (RTK), had no effect
(Figure 6H). Therefore, a GPCR might also be involved in
the release of HBP induced by SLY in addition to TLR4. The
mechanism could be complex, and further studies are necessary
to explain why two receptors are involved in the release of HBP
induced by SLY.
Suilysin Increased Vascular Leakage in
Mice
The effects of SLY on vascular leakage were tested in 8-week-
old female C57BL mice using the Miles assay. Supernatants
of the wild-type 05ZYH33 strain and the C1sly mutant
significantly increased the leakage of Evans blue dye in mice
compared with a THB control or the supernatants from the
1sly mutant (05ZYH33-sup: 18.96 ± 1.35 µg/mL vs. 1sly-sup:
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FIGURE 3 | Suilysin secreted from 05ZYH33 induced the release of HBP from PMNs. (A) The release of HBP from whole blood samples was induced by
supernatants of 05ZYH33 but not by the bacterial cells. Human whole blood samples were incubated with PBS, THB, 05ZYH33 bacterial cells, or 05ZYH33
supernatants for 30 min at 37◦C. The HBP level in the supernatants was measured by ELISA. PBS was considered as the background and THB was used as a
negative control. An unpaired Student’s t-test was used for the statistical analysis. (B) Heat treatment of the supernatants significantly reduced the release of HBP
from whole blood samples. The supernatants were treated at 100◦C for 5 min before being added to whole blood samples. (C) A SDS-PAGE analysis of the elution
fraction from anion-exchange and hydrophobic interaction chromatography, which induced the maximal release of HBP. (D) LDH failed to induce the release of HBP
from PMNs. The PMNs were incubated with His-LDH or Trix-LDH at 0.1, 1.0, or 10 µg/mL for 30 min at 37◦C. (E) Suilysin in the 05ZYH33-supernatant stimulated
the PMNs to secret HBP. Human whole blood samples were incubated with PBS, THB, the 05ZYH33-supernatant, the 1sly-supernatant or the C1sly-supernatant
for 30 min at 37◦C. (F) Western-blot analysis of the HBP that was released from PMNs incubated with cultures of wild-type 05ZYH33, the 1sly mutant, or purified
nSLY. A representative image is presented. ∗∗∗P < 0.001, ∗∗P < 0.01, n.s., not significant. ELISA data are expressed as the mean ± SD of at least four independent
experiments.
12.38 ± 0.57 µg/mL, P = 0.0008, Figures 7A,B), implying
that SLY contributes to vascular leakage. In addition, the
05ZYH33 supernatant failed to induce vascular leakage in Tlr4
knockout mice (TLR4+/+: 26.80 ± 1.96 µg/mL vs. TLR4−/−:
11.35 ± 0.98 µg/mL, P < 0.0001, Figures 7C,D). These in vivo
data support the essential role of TLR4 in vascular leakage
mediated by SLY.
DISCUSSION
Since the two large outbreaks of S. suis human infections occurred
in China, sporadic cases of S. suis-associated STSS have been
reported worldwide (Tramontana et al., 2008; Gomez et al.,
2014). This indicates that S. suis has already become a persistent
problem, and the potential for a large-scale outbreak exists.
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FIGURE 4 | Suilysin induced PMN degranulation. (A) Superoxide anion production was not affected by treatment with nSLY or 05ZYH33 supernatants. Purified
PMNs were incubated with 0.50, 0.75, or 1.0 µg/mL nSLY, the 05ZYH33-supernatant, or HBSS for 30 min at 37◦C. Following treatment, the cells were stimulated
with 200 ng/ml PMA in the presence of 0.1 mM cytochrome C. The superoxide anion production was determined by measuring the absorbance at 550 nm. Data are
expressed as the mean ± SD of three independent experiments. (B) Western blot analysis of release of HBP from PMNs that were treated as described for the
measurement of superoxide anion production. Thirty microliters of each sample was loaded in each lane. A representative image is presented. (C,D) Scanning
electron microscopy images of purified PMNs that were pre-incubated with HBSS (C) or 1 µg/mL nSLY (D). Red arrows indicate excessive membrane ruffles.
Representative images are presented. The scale bar represents 5 µm. (E–G). Levels of membrane-associated marker proteins for PMN degranulation, CD63 (E),
CD11b (F), and CD66b (G) were increased by 1 µg/mL rSLY. PMNs were stimulated with HBSS as a negative control (—), SLY-isotype (—), rSLY (—), or rFhb (—)
and analyzed by flow cytometry. (H,I) Levels of granule marker proteins for PMN degranulation, elastase (H) and lactoferrin (I) were increased by 1 µg/mL nSLY or
the 05ZYH33 supernatant. ∗∗∗P < 0.001, ∗∗P < 0.01. ELISA data are presented as the mean ± SD of at least three independent experiments.
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FIGURE 5 | SLY induced a Ca2+ influx and the release of HBP was dependent on the Ca2+ influx. (A) The SLY-induced release of HBP from human whole
blood samples was abolished by EGTA. PMNs were pre-incubated with EGTA (10 mM) for 1 h at 37◦C. ∗∗∗P < 0.001. (B) SLY induced a Ca2+ influx. Positive
control fMLP, negative control LPS, nSLY, nSLY with pre-incubation of EGTA or with Ca2+-free HBSS, rSLY, non-hemolytic SLY mutant P353V was added to a
confocal small dish containing purified PMNs loaded with the fluorescent Ca2+ indicator Fluo-3/AM at the indicated time (60 s, arrow), and Ca2+ mobilization was
monitored by real-time fluorescence microscopy for 250 s. (C) SLY in the 05ZYH33-supernatant stimulated a Ca2+ influx. The positive control was fMLP, the
negative control was LPS, and the 05ZYH33-supernatant, THB, the 1sly-supernatant, the 05ZYH33-supernatant with pre-incubation of EGTA were used as
stimulants. The fluorescence intensity of at least eight cells in one vision was measured and the mean increase intensity is presented.
Although a great deal of effort has been spent on S. suis, the
pathogenic mechanism of STSS associated with S. suis remains
poorly understood. The results of this study demonstrated that
SLY secreted by the highly virulent S. suis strain 05ZYH33
stimulated the release of HBP from the PMNs and induced
vascular leakage in mice, indicating a role for SLY in the
development of STSS. An in-depth investigation of the molecular
mechanism underlying the release of HBP from PMNs mediated
by SLY revealed that the release of the HBP occurred via
Ca2+-influx dependent degranulation and required both the p38
MAPK and PI3K signaling pathways.
Suilysin is a member of the CDC toxin family. It comprises 497
amino acids and exhibits hemolytic activity. SLY was considered
as a putative virulence factor when it was first purified (Jacobs
et al., 1994). However, studies investigating the association of
SLY with the virulence of S. suis yielded conflicting results.
A sly deletion mutation did not appear to affect the virulence
of S. suis in piglets although it did impact the virulence in
mice (Allen et al., 2001; Lun et al., 2003). Immunization with
purified SLY failed to induce significant protection against S. suis
infection in piglets (Jacobs et al., 1996). Moreover, virulent
S. suis strains from North America do not have the sly gene in
their genome (Gottschalk et al., 1998). These findings seem to
support the view that SLY is not an essential virulence factor of
S. suis. In contrast, we conducted a study in which SLY levels
in different S. suis strains were compared. That study showed
that the highly virulent strain 05ZYH33, which caused higher
mortality and greater damage to PMNs and human umbilical
vein endothelial cells than non-epidemic strains, expressed a
higher level of SLY than less virulent strains (He et al., 2014).
In addition, a sly deletion markedly reduced the virulence
of 05ZYH33 in mice (He et al., 2014). However, Gottschalk
et al. thought that the higher toxicity of the Chinese ST7
strain for human peripheral blood mononuclear cells could
simply be the result of its higher capacity to release SLY (Ye
et al., 2006, 2009; Gottschalk et al., 2010). These results suggest
that SLY is associated with the high virulence of the Chinese
strain.
The role of SLY in the mediation of the inflammatory response
is also controversial. Segura et al. (2006) suggested that SLY
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FIGURE 6 | Receptor and signal molecule were involved in the Suilysin induced release of HBP. (A,B) The release of HBP was blocked by the
TLR4-specific inhibitor CLI-095 (3 µM; A) and the TLR4-non-specific inhibitor OxPAPC (30 µg/mL; B). (C,D) The release of HBP was not affected by the PLC and
(Continued)
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FIGURE 6 | Continued
PLA2 inhibitor U73122 (10 µM; C) and the ERK1/2 inhibitor PD98095 (20 µM; D). (E–H) The release of HBP was blocked by the p38 MAPK inhibitor SB203580
(10 µM; E), the PI3K inhibitor Wortmannin (1.0 µM; F), the GPRP inhibitor PTX (0.15 µg/mL; G) but not by the RTK inhibitor Genistein (100 µM; H). The PMNs were
pre-treated with or without the inhibitors at 37◦C for 1 h (PTX for 3h and CLI-095 for 6 h) before a 30 min incubation with the stimulants at 37◦C. The HBP level was
measured by ELISA. The HBP level relative to the total amount of HBP in the cell lysate from treatment with Triton X-100 was calculated. The data are expressed as
the mean ± SD of at least four independent experiments. ∗∗∗P < 0.001. n.s., not significant.
FIGURE 7 | Suilysin increased the vascular leakage in C57BL mice. (A,B) SLY increased the vascular leakage in mice. C57BL/6J mice were intradermally
injected with THB, the 05ZYH33-supernatant, the 1sly-supernatant, or the C1sly-supernatant. Four hours later, Evans blue dye (2.5%, 100 µL) was injected via the
tail vein. After 30 min, photographs of the skin area containing the extravasated protein-bound dye were taken, and the dye was extracted from the skin using
formamide. Dye concentrations were measured at 630 nm using a spectrophotometer. (C,D) The 05ZYH33 supernatant did not induce vascular leakage in Tlr4
knockout mice. TLR4+/+ and TLR4−/− were treated in the similar ways as in (A,B). ∗∗∗P < 0.001, ∗∗P < 0.01, n.s., not significant.
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might only play a limited role in stimulating the release of
pro-inflammatory cytokines, and the consequent inflammatory
response. They found an increase in the mRNA and protein levels
of pro-inflammatory cytokines that did not appear to be affected
in a SLY-negative mutant strain compared with a wild-type S. suis
strain (Segura et al., 2006). They also showed that purified SLY
did not stimulate the production of tumor necrosis factor alpha
(TNF-α) or interleukin-6 (IL-6) in murine macrophages (Segura
et al., 1999). In contrast, Lun et al. found that rSLY triggered
the release of TNF-α and IL-6 from human and pig monocytes
(Lun et al., 2003). The intraperitoneal injection of a recombinant
SLY resulted in a significant increase in the serum IL-6 levels
in C57BL/6 mice (Du et al., 2009). This discrepancy might be
attributable to the various SLY activities obtained with different
purification methods or because different S. suis strains were
used in these studies. HBP has been proven to be an important
inflammatory mediator that can recruit and activate monocytes
(Pereira et al., 1990; Lee et al., 2003; Soehnlein et al., 2005). To
our knowledge, SLY from the highly virulent strain 05ZYH33 was
found to induce the release of HBP from PMNs for the first time
in this study.
In this study, we also found that, in addition to activating
intracellular signaling pathways including the p38 MAPK and
PI3K pathways, SLY also induced a Ca2+ influx in the
PMNs. Mobilization of cytosolic free Ca2+ and cytoskeletal
rearrangement have been demonstrated as requirements for
degranulation in PMNs (O’Flaherty et al., 1991; Lacy, 2006; Lacy
and Eitzen, 2008). In this study, removal of the extracellular
Ca2+ by chelation with EGTA completely abolished the release
of HBP, further supporting a critical role for a Ca2+ influx
in PMN degranulation. Furthermore, we found that a non-
hemolytic SLY mutant (P353V) failed to induce a Ca2+ influx
(Figure 5B) and the release of HBP (Supplementary Figure S1),
also indicating that the release of HBP is Ca2+ dependent.
By directly monitoring the intracellular Ca2+ concentration,
we provided direct evidence for the first time to support that
SLY induced a Ca2+ influx. The underlying mechanism of
the Ca2+ influx induced by SLY will be determined in future
studies.
Until now, the molecular and pathological mechanisms
underlying STSS that is not associated with GAS have been
poorly understood. In this study, we found that mitilysin
secreted from Streptococcus mitis and vaginolysin released from
Streptococcus viridans, also belong to the CDC toxin family
and may share a similar crystal structure with SLY, because
they share 49 and 51% sequence identities, respectively, with
the primary protein sequence of SLY. This indicates that these
two toxins may have a similar function in the host cell.
These two opportunistic pathogens may induce the release of
HBP and cause vascular leakage when they enter the human
bloodstream, and lead to STSS with severe vascular leakage.
To some extent, these phenomena may be involved in the
STSS cases caused by S. mitis in 1991 in the Yangtze River
Delta of China (Lu et al., 2003). On the other hand, other
CDC toxins such as anthrolysin O, perfringolysin O, listeriolysin
O, and streptolysin O, may also lead to the release of HBP
in humans. Because HBP has already been considered as a
potential biomarker for septic shock (Linder et al., 2009, 2012;
Chew et al., 2012), these toxins could be a possible reason
for the release of HBP in septic shock caused by related
strains.
In summary, we reported for the first time in this study that
SLY from the highly virulent S. suis strain 05ZYH33 induced the
release of HBP from PMNs in a Ca2+ influx-dependent manner
and increased vascular leakage in mice. We provided new insights
into vascular leakage in STSS not associated with the GAS, which
might lead to the discovery of potential therapeutic targets for
S. suis-associated STSS.
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